Medical/Pharmaceuticals
NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Begin Trading on NYSE in Record Transfer
NEW YORK, Feb. 2, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market update + AstraZeneca Shares Beg...
2026-02-02 22:39
10498
3Shape TRIOS 6 intraoral scanner wins the European Product Design Award (EPDA) 2025
COPENHAGEN, Denmark, Feb. 2, 2026 /PRNewswire/ -- 3Shape today announced that theTRIOS 6 intraoral scanner has been honored with the European Product Design Award (EPDA) 2025 in the category Industrial/Healthcare: Medical Products. The EPDA Award Statement: "TRIOS 6 combines cutting-edge functio...
2026-02-02 20:03
4815
DHL Health Logistics Singapore Expands Capabilities to Elevate Life Science & Healthcare Logistics
Strategic expansion positions Singapore as a strategic arm for healthcare logistics in the APAC region. * DHL Group invests €10 million in a new pharmaceutical hub in Singapore to enhance international logistics and healthcare logistics infrastructure across the Asia-Pacific region. * The ex...
2026-02-02 10:00
8407
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to implant FDA-approved novel defibrillation lead
The new technology is the world's smallest, catheter-delivered defibrillation lead AUSTIN, Texas, Feb. 2, 2026 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to implant an FDA-approved no...
2026-02-02 09:08
4690
International Cancer Organizations Work Together to Meet the Needs of Women with Cancer in Vietnam
The National Comprehensive Cancer Network (NCCN) is collaborating with the Vietnam National Cancer Hospital (K Hospital) to adapt regional recommendations for treating breast and ovarian cancers. HANOI, Vietnam, Feb. 2, 2026 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an a...
2026-02-02 09:08
4951
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Adult Type 2 Diabetes
HANGZHOU, China, Jan. 30, 2026 /PRNewswire/ -- Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National Medical Products Administration (NMPA) has approved ...
2026-01-30 19:54
7839
Philips Receives Frost & Sullivan's 2025 Global Enabling Technology Leadership Recognition for Excellence in Digital Pathology-Healthcare Informatics
Philips is recognized for its market-leading innovation and comprehensive
digital pathology ecosystem, driving global transformation in diagnostics and
healthcare informatics
SAN ANTONIO, Jan. 30, 2026 /PRNewswire/ -- Frost & Sullivan
2026-01-30 02:00
8593
Zeus Launches PFX™ Platform and Introduces PFX Flex™ Sub-Lite-Wall™, Advancing the Future of Catheter Innovation
Polymer platform sets a new standard for catheter design with PTFE-like performance and expanded material flexibility ORANGEBURG, S.C., Jan. 29, 2026 /PRNewswire/ -- Zeus, a global leader in advanced polymer solutions, today announced the launch of PFX™, a breakthrough platform designed to advan...
2026-01-29 23:00
7260
Hope Rising in Hainan: International NUT Carcinoma Center Launches in Boao
BOAO, China, Jan. 29, 2026 /PRNewswire/ -- The International NUT Carcinoma Diagnosis and Treatment Center has been inaugurated at Boao International Hospital. Established through a collaboration between Boao International Hospital and Chongqing University Three Gorges Hospital, this center tackle...
2026-01-29 20:00
6078
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously reported placebo-controlled Phase III trial couple...
2026-01-29 19:00
10953
SK bioscience Initiates International Phase 1/2 Clinical Trial of Universal Vaccine Candidate Targeting Sarbecovirus Family
* Global phase 1/2 clinical trial initiated for GBP511, a vaccine targeting the Sarbecovirus Family * Next-generation vaccine leveraging SKYCovione's recombinant protein-based platform and nanoparticle technology * SK bioscience will continue to strengthen a Mid- to Long-Term global vaccine...
2026-01-29 10:10
7998
First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of68Ga-PSMA-11) for prostate cancer imaging i...
2026-01-29 07:43
8288
REPROCELL Launches StemEdit - Clinical Gene Editing Services and New iPSC Lines Using AI-Designed editing tools
BELTSVILLE, Md., Jan. 29, 2026 /PRNewswire/ -- REPROCELL today announced the commercial launch ofStemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveragingOpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEd...
2026-01-28 22:00
5787
NYSE Content Advisory: Pre-Market Update + First Lady Melania Trump to Ring NYSE Bell for Doc 'Melania'
NEW YORK, Jan. 28, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + First Lady Melania Tr...
2026-01-28 21:55
8143
Sciwind Biosciences Published T2DM Phase III EECOH-1 Trial Results of Ecnoglutide in Nature Communications
HANGZHOU, China, Jan. 28, 2026 /PRNewswire/ -- Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind Biosciences Co., Ltd. ("Sciwind"), for the monotherapy of type 2 diabetes (T2DM), have been published in Nature Communications. Con...
2026-01-28 19:39
7238
CHCC 2026 Opens Registration, Offering a One-Stop Platform for Hospital Construction Solutions and Real-World Applications
TIANJIN, China, Jan. 28, 2026 /PRNewswire/ -- The 27th China Hospital Construction Conference & International Hospital Build and Infrastructure Exposition (CHCC 2026), a globally recognized hospital construction event, will be held from May 23 to 25, 2026, at the National Convention and Exhibitio...
2026-01-28 15:01
6015
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy
The US Food and Drug Administration (FDA) has approved Novo Nordisk's new once-daily pill for weight management, designed to help people reduce excess body weight and maintain weight reduction over the long term. In clinical trials, patients achieved an average weight reduction of 16.6% from base...
2026-01-28 10:45
8276
Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural history expected worsening of cUHDRS in symptomatic patients of -0.73 points over nine months, based on propensity score weighting. Skyhawk also ann...
2026-01-27 21:00
9180
Libevitug Approved in China as First-in-Class Hepatitis D Treatment
BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a hum...
2026-01-27 16:15
6987
Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030
* Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. * Growth over the financial year was driven by increased sales in oncology, particularly in the United States. * Several partnership agreements in oncology and neurology strengthen the Group's R&D portfoli...
2026-01-27 16:00
5328
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 293 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
9175
QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration
2026-09-12 09:00
8317
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7584
